NMC
MCID: NTM002
MIFTS: 44

Nut Midline Carcinoma (NMC)

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Nut Midline Carcinoma

MalaCards integrated aliases for Nut Midline Carcinoma:

Name: Nut Midline Carcinoma 12 58 15 17 71
Nuclear Protein in Testis Midline Carcinoma 12
Nmc 58

Characteristics:

Orphanet epidemiological data:

58
nut midline carcinoma
Inheritance: Not applicable;

Classifications:



External Ids:

Disease Ontology 12 DOID:0060463
NCIt 49 C45716
ICD10 via Orphanet 33 C80.9
Orphanet 58 ORPHA443167
UMLS 71 C1707291

Summaries for Nut Midline Carcinoma

Disease Ontology : 12 A carcinoma that is characterized by a BRD4-NUT translocation involving the rearrangement of the bromodomain-containing protein 4 (BRD4) and the gene encoding nuclear protein of the testis (NUT) at 15q14, BRD4-NUT t(15;19)(q14;q13.1) and arises from midline epithelial structures, most commonly the head, neck, and mediastinum.

MalaCards based summary : Nut Midline Carcinoma, also known as nuclear protein in testis midline carcinoma, is related to adenoid cystic carcinoma and blastic plasmacytoid dendritic cell. An important gene associated with Nut Midline Carcinoma is NUTM1 (NUT Midline Carcinoma Family Member 1), and among its related pathways/superpathways are Chromatin organization and Chromatin Regulation / Acetylation. The drugs Rucaparib and Azacitidine have been mentioned in the context of this disorder. Affiliated tissues include testis, lung and tonsil, and related phenotypes are leukemia and ewing sarcoma

Wikipedia : 74 NUT carcinoma (formerly NUT midline carcinoma), is a rare genetically defined, very aggressive squamous... more...

Related Diseases for Nut Midline Carcinoma

Diseases related to Nut Midline Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 76)
# Related Disease Score Top Affiliating Genes
1 adenoid cystic carcinoma 30.3 SOX2 MYC KMT2C EP300
2 blastic plasmacytoid dendritic cell 10.6 MYC BRD4
3 rapidly involuting congenital hemangioma 10.5
4 rare tumor 10.5
5 hereditary lymphedema i 10.4 MYC KDM4C H2AC18
6 pelizaeus-merzbacher disease 10.4 SOX2 MYC H2AC18
7 chromosome 16p13.3 deletion syndrome, proximal 10.4 KDM4C H2AC18 EP300
8 luminal breast carcinoma 10.4 MYC KDM4C H2AC18
9 kleefstra syndrome 1 10.3 KMT2C KDM4C H2AC18
10 colonic benign neoplasm 10.3 MYC KDM4C H2AC18
11 hypotrichosis 1 10.3 MYC KDM4C H2AC18
12 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.3
13 lymphoepithelioma-like thymic carcinoma 10.3 NUTM1 BRD4
14 lymphatic system cancer 10.3 MYC KDM4C H2AC18
15 weaver syndrome 10.3 NSD3 KDM4C H2AC18
16 mature b-cell neoplasm 10.3 MYC KDM4C H2AC18
17 intestinal benign neoplasm 10.3 MYC KDM4C H2AC18
18 retinitis pigmentosa 11 10.3 MYC KDM4C H2AC18
19 bile duct adenocarcinoma 10.3 MYC KDM4C H2AC18
20 cornelia de lange syndrome 10.3 SOX2 MYC H2AC18 EP300
21 lymphatic system disease 10.3 MYC KDM4C H2AC18
22 retinal cancer 10.3 MYC KDM4C H2AC18
23 rhabdoid cancer 10.3 KDM4C H2AC18 BRD9
24 germ cells tumors 10.3
25 malignant ovarian surface epithelial-stromal neoplasm 10.3 MYC KDM4C H2AC18
26 germ cell and embryonal cancer 10.3 SOX2 MYC KDM4C H2AC18
27 infratentorial cancer 10.3 SOX2 MYC KDM4C H2AC18
28 ovary epithelial cancer 10.3 MYC KDM4C H2AC18
29 ocular cancer 10.3 SOX2 MYC KDM4C H2AC18
30 germ cell cancer 10.2 SOX2 MYC KDM4C H2AC18
31 central nervous system cancer 10.2 SOX2 MYC KDM4C H2AC18
32 bone marrow cancer 10.2 MYC KDM4C H2AC18
33 suppression of tumorigenicity 12 10.2 SOX2 MYC KDM4C H2AC18
34 large cell medulloblastoma 10.2 MYC KDM4C
35 kabuki syndrome 1 10.2 KMT2C KDM4C H2AC18
36 disease of mental health 10.2
37 learning disability 10.2
38 arterial thoracic outlet syndrome 10.2
39 ewing sarcoma 10.2
40 spastic paraplegia, intellectual disability, nystagmus, and obesity 10.2
41 thymic carcinoma 10.2
42 salivary gland carcinoma 10.2 SOX2 H2AC18 BRD3
43 lynch syndrome 10.1 KDM4C H2AC18 EP300 DCC
44 47,xyy 10.1
45 lung cancer 10.0
46 small cell carcinoma 10.0
47 tonsillitis 10.0
48 sarcoma 10.0
49 respiratory failure 10.0
50 acute leukemia 10.0

Graphical network of the top 20 diseases related to Nut Midline Carcinoma:



Diseases related to Nut Midline Carcinoma

Symptoms & Phenotypes for Nut Midline Carcinoma

Human phenotypes related to Nut Midline Carcinoma:

58 31 (show all 9)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 leukemia 58 31 frequent (33%) Frequent (79-30%) HP:0001909
2 ewing sarcoma 58 31 frequent (33%) Frequent (79-30%) HP:0012254
3 neuroblastoma 58 31 frequent (33%) Frequent (79-30%) HP:0003006
4 abnormality of the mediastinum 58 31 frequent (33%) Frequent (79-30%) HP:0045026
5 oropharyngeal squamous cell carcinoma 58 31 frequent (33%) Frequent (79-30%) HP:0012182
6 pancreatoblastoma 58 31 frequent (33%) Frequent (79-30%) HP:0100757
7 pancreatic squamous cell carcinoma 58 31 occasional (7.5%) Occasional (29-5%) HP:0012142
8 neoplasm 58 Very frequent (99-80%)
9 squamous cell carcinoma 58 Frequent (79-30%)

GenomeRNAi Phenotypes related to Nut Midline Carcinoma according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.63 CDK9
2 Decreased viability GR00221-A-1 10.63 BRD4 BRDT MYC BRD2 CDK9 SOX2
3 Decreased viability GR00221-A-2 10.63 BRDT DCC BRD2 CDK9 EP300
4 Decreased viability GR00221-A-3 10.63 BRD4 BRDT DCC MYC
5 Decreased viability GR00221-A-4 10.63 BRD4 BRDT DCC BRD2 CDK9 SOX2
6 Decreased viability GR00301-A 10.63 BRD2
7 Decreased viability GR00342-S-3 10.63 BRDT
8 Decreased viability GR00402-S-2 10.63 BRD4 BRDT DCC MYC BRD2 CDK9
9 Decreased substrate adherent cell growth GR00193-A-1 9.63 BRD4
10 Decreased substrate adherent cell growth GR00193-A-2 9.63 BRD2 BRD3 BRD4 CDK9
11 Decreased substrate adherent cell growth GR00193-A-3 9.63 CDK9
12 Transferrin accumulation in the perinuclear area GR00356-A-3 8.92 BRD2 BRD3 BRD4 CDK9

MGI Mouse Phenotypes related to Nut Midline Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 9.77 BRD2 BRD9 CDK9 DCC DOT1L EP300
2 neoplasm MP:0002006 9.1 DCC DOT1L EP300 KDM4C MYC SOX2

Drugs & Therapeutics for Nut Midline Carcinoma

Drugs for Nut Midline Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 13)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rucaparib Approved, Investigational Phase 1, Phase 2 283173-50-2 9931954
2
Azacitidine Approved, Investigational Phase 1, Phase 2 320-67-2 9444
3
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
4
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314